Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Impact BioMedicalIBO -1.57%10 Forward Dividend Yield % is 0.00% as of Aug. 14, 2026. GuruFocus rates IBO with a GF Score™ of 10/100. The stock has 6 warning signs investors should review. Among 149 Biotechnology companies, Impact BioMedical ranks worse than 671140.27% on this metric.
As of today (2026-08-14), the Forward Annual Dividend Yield of Impact BioMedical is 0.00%.
As of today (2026-08-14), the Trailing Annual Dividend Yield of Impact BioMedical is 0.00%.
IBO's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.23 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Impact BioMedical Forward Dividend Yield % Related Terms
IBO vs ATYR, MCRB, TIL: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Impact BioMedical's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Impact BioMedical Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Impact BioMedical's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Impact BioMedical's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Impact BioMedical (IBO) has a Forward Dividend Yield % of 0.00% as of Aug. 14, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Impact BioMedical and its competitors. According to the industry distribution chart, Impact BioMedical ranks #999999 out of 149 companies in the Biotechnology industry.
Is Impact BioMedical's Forward Dividend Yield % too high?
Impact BioMedical's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Impact BioMedical ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Impact BioMedical has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Impact BioMedical's Forward Dividend Yield % compare to ATYR and MCRB?
According to the Biotechnology industry distribution chart, Impact BioMedical ranks #999999 out of 149 companies for Forward Dividend Yield %. This places Impact BioMedical in the lower half of its industry. The industry median Forward Dividend Yield % is 1.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.23, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Impact BioMedical and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Impact BioMedical's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impact BioMedical stock overvalued right now?
Impact BioMedical (IBO) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Impact BioMedical's overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Impact BioMedical (IBO), the current Forward Dividend Yield % is 0.00% as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
10GF Score
Get the complete analysis for IBO
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IBO has been successfully added to your 
